Stock Research Monitor: MDCO, PCRX, and SCYX
LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on MYL sign up now at www.wallstequities.com/registration. On Friday, the NASDAQ Composite ended the day at 7,737.42, down 1.46%; the Dow Jones Industrial Average edged 0.30% lower, to finish at 25,451.06; and the S&P 500 closed at 2,818.82, marginally slipping 0.66%. Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Drugs - Generic stocks: The Medicines Co. (NASDAQ: MDCO), Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and SCYNEXIS Inc. (NASDAQ: SCYX). All you have to do is sign up today for this free limited time offer by clicking the link below.
Parsippany, New Jersey-based The Medicines Co.'s stock finished Friday's session 1.53% lower at $39.28 with a total trading volume of 412,170 shares. The stock has gained 11.09% in the past month and 29.89% over the past three months. The Company's shares are trading above their 50-day and 200-day moving averages by 7.89% and 22.64%, respectively. Moreover, shares of Medicines Co., which provides medicines to treat acute and intensive care patients, have a Relative Strength Index (RSI) of 56.72. Get the full research report on MDCO for free by clicking below at:
Shares in Canonsburg, Pennsylvania headquartered Mylan N.V. rose 0.33%, ending last Friday's session at $36.22 with a total trading volume of 2.25 million shares. The Company's shares are trading below their 50-day moving average by 5.12%. Moreover, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have an RSI of 44.01. The free technical report on MYL can be accessed at:
On Friday, Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.'s stock saw a rise of 0.49%, to close the day at $41.00. A total volume of 810,217 shares was traded, which was higher than their three months average volume of 632.97 thousand shares. The Company's shares have advanced 34.21% in the last month and 21.84% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 15.35% and 12.24%, respectively. Additionally, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 71.41. Sign up for free on Wall St. Equities and claim the latest report on PCRX at:
Shares in Jersey City, New Jersey headquartered SCYNEXIS Inc. ended the day 4.09% lower at $1.64. A total volume of 420,975 shares was traded. The stock has gained 33.33% in the previous three months. The Company's shares are trading below their 50-day moving average by 5.95%. Furthermore, shares of SCYNEXIS, which develops and commercializes anti-infectives to address unmet therapeutic needs, have an RSI of 40.01.
On July 11th, 2018, research firm Needham upgraded the Company's stock rating from ‘Hold' to ‘Buy', with a target price of $5 per share. See the free research coverage on SCYX at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities